Clement Kabakama

About

Dr Kabakama is a Clinician,Resident Cardiology Fellow ,Cardiovascular Researcher with More than seven Years in a Public Health Research, With immense Passion for Preventing Rheumatic Heart Disease(RHD), under a Working Programme to strengthen (RHD)Primordial Prevention Primary Prevention and Secondary Prevention with the emphasis of Sustainable Development Goals (SDG3.b). With Particular interest on development of a group A streptococcal Vaccines(strep A vaccine). Currently Working as the Researcher Fellow at the New East African Centre of Excellence for Cardiovascular Sciences (EACoECVS)-Mloganzila Campus,Developing a Capacity building for Primary health Care providers(HCW)on Advocacy Awareness for Acute Rheumatic Fever (ARF) and Rheumatic Heart Disease (RHD), Among at Risk Community in the Country,(endemic Regions). Clement is International Visiting Scholar at University of Cape Town ,Where Collaborates with The Heart of Africa Research Group ,Cape Heart Institute (CHI) based at UCT University of Cape Town &Groote Schuur Hospital, South Africa. Before joining MUHAS, Dr. Kabakama worked as a Resident Fellow for his International Clinical Rotation Posted at a National Cardiac Institute (JKCI), Jakaya Kikwete Cardiac Institute at Muhimbili National Hospital (MNH) as a Cardiology fellow Residency in the Department of Adult Cardiology – (Cardio -1). Dr.Kabakama ,Participated in one of the Multicentric Trial known as the INVICTUS Trial , and was appointed as the NLO-National Leader Officer for Tanzania INVICTUS Sites(Muhimbili University/JKCI Hospital -Dar es salaam,Benjamin Mkapa Hospital- Dodoma,Mbeya Referral Region Hospital-Mbeya) where in the Study Hypothesized that Patients with rheumatic valvular heart disease(RVHD) and who are in atrial fibrillation or Flutter(AF/Flutter) and have other stroke risk factors, Rivaroxaban is Non-inferior to Vitamin K antagonist(VKAs) for Prevention of Stroke or Sytemic Embolism. The Patients with RVHD either with AF/Flutter but unsuitable for VKA Therapy or with Sinus rhythm but with High risk, Rivaroxaban is superior to Asprin for Prevention of stroke or Systemic embolism. To this TRIAL co-ordinated all the activities for Recruiting Patients, Documentations, Ethics Regulatory Submissions Reports, ADRs (Adverse event Reporting) to the Local Regulatory Authority, Supervised the Project Staffs on adherence of conducting Trial as per Protocol, as well reporting any discrepancies observed to Programme Managers based in Canada at Population Health Research Institute (PHRI), PHRI Has been a Global Leader in Large clinical trials and Population health observational STUDIES for Over a Decade. Presently Dr Kabakama is a Project Lead for Strep A Research Programme ( Strep A REGISTRY ) is a Collaborative Study that aims to Establish the First ( Strep A Registry ) in Tanzania and Biorepository of Laboratory-Confirmed GAS isolates in One of Endemic Region,Babati- Manyara with One of its main Objective being to Collect a Comprehensive epidemiological Clinical Microbiological and Molecular Data for (GAS), iGAS , iNfection(s) in Primary School Children.

Education

Publications